Lisa Klock, DO
Family Medicine · Des Moines, IANPI 1891707832
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 566 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 566 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$1K
- AstraZeneca$951
- Boehringer Ingelheim$495
- Lilly USA, LLC$444
- Astellas Pharma US Inc$409
- plus $3K from 39 others
What the payments were for
- Food & beverage$8,83498%
- Education$1362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,969 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 41 | $60,025 |
| TrulicityDulaglutide | 44 | $59,092 |
| OzempicSemaglutide | 51 | $54,348 |
| JanuviaSitagliptin Phosphate | 12 | $15,962 |
| EliquisApixaban | 11 | $14,748 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $14,711 |
| Spiriva RespimatTiotropium Bromide | 15 | $13,904 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $11,847 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $10,008 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $8,397 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,621 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $7,372 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,573 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 224 | $6,309 |
| Dexlansoprazole DrDexlansoprazole | 17 | $6,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $495 | $83,93773 claims |
| Lilly USA, LLCTrulicity | $444 | $59,09244 claims |
| Novo NordiskOzempic | $272 | $54,34851 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $951 | $20,29839 claims |
| MerckJanuvia | $282 | $15,96212 claims |
| PfizerEliquis | $1,310 | $14,74811 claims |
| GSKBreo Ellipta | $28 | $7,62119 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $187 | $6,57314 claims |
| AbbVieSynthroid | $1,993 | $1,57523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Des Moines
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
- Dylan LoweDes Moines$105K
- Kristin GisselmanDes Moines$8K
- Kirk PetersonHuxley$576K
- Nicholas GoetschWaterloo$525K
- Stephen HarrisonClinton$249K
- Leslie George PaulsenMuscatine$136K
- Michael AbouassalyWest Burlington$88K
- Kevin DeregnierWinterset$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.